SLU-PP-332 TabletsCapsules
ERR agonist studied for metabolism and endurance.
- Status
- Research / not approved
- Developer
- Thomas P. Burris laboratory (Saint Louis University / University of Florida)
- Receptors / target
- Pan-agonist of estrogen-related receptors ERRalpha/beta/gamma (orphan nuclear receptors); drives mitochondrial biogenesis, oxidative phosphorylation and fatty-acid oxidation
- FDA-approved?
- NO
- Prescription available?
- NO
- Studied for
- exercise mimetic / endurance (mouse)obesity & metabolic syndrome (mouse)mitochondrial function & fatty-acid oxidationskeletal-muscle oxidative-fiber remodeling
Overview
SLU-PP-332 is a synthetic small molecule — not a peptide, despite being sold as "SLU-PP-332 Tablets" — developed in the laboratory of Thomas P. Burris. It is an investigational research compound that has never been tested in humans; all evidence is preclinical (mouse and in-vitro). It drew attention as a candidate "exercise mimetic": in mice it reproduces molecular and physiological hallmarks of aerobic exercise — more oxidative muscle fibers, higher fat oxidation and greater endurance — without the animal exercising more. It is research-use-only and not FDA-evaluated.
Mechanism
SLU-PP-332 is a pan-agonist of the estrogen-related receptors (ERRalpha/beta/gamma) — orphan nuclear receptors that are master regulators of cellular energy metabolism, governing mitochondrial biogenesis, oxidative phosphorylation, fatty-acid oxidation and the Krebs cycle, and essential for skeletal-muscle endurance adaptation. It is most potent at ERRalpha. In mice it triggers an ERRalpha-dependent "acute aerobic exercise" transcriptional program in skeletal muscle, increasing oxidative fibers, mitochondrial respiration and running capacity — effects lost when ERRalpha signaling is removed.
Clinical evidence
There is no clinical evidence — SLU-PP-332 has never entered human trials. Every finding is preclinical: ERRalpha-dependent endurance gains in mice (ACS Chemical Biology 2023); ~12% weight loss, improved glucose tolerance and reduced hepatic fat in obese mice without appetite suppression (JPET 2024); and medicinal-chemistry/optimization work (Int J Biol Macromol 2026). Notably the compound is poorly orally bioavailable, which led the same lab to develop an orally active successor, SLU-PP-915 (JPET 2026). None of these rodent results can be extrapolated to human weight loss or endurance.
Safety profile
The human safety of SLU-PP-332 is entirely unknown — it has never been given to humans, and no clinical adverse-event, pharmacokinetic or toxicology data exist. Even in animals, characterization is limited to short-term dosing; there are no chronic-toxicity, cardiovascular-safety, reproductive or carcinogenicity studies. A specific theoretical concern is that ERRs are highly expressed in the heart and other high-energy tissues, so sustained pan-ERR activation could carry cardiac or off-target risks that have not been evaluated. It is sold strictly research-use-only; the "tablet" framing does not reflect any validated human formulation. As an exercise-mimetic class it is of plausible anti-doping interest but is not currently named on the WADA list (status reported as unknown). Safety and human-data confidence are both scored at the floor.
- No human time-course
There are no human trials. In mice, endurance and metabolic effects appeared over days-to-weeks of dosing, but the compound is poorly orally bioavailable; any human timeline is unverified.
Reported in published literature and user reports. Not a complete list, and not medical advice.
- Unstudied in humans — no human safety data exist
- No human adverse-event profile established
- Broad ERR activation in heart/muscle is a theoretical off-target/cardiac concern (uncharacterized)
- No chronic-toxicity, reproductive or carcinogenicity data
If severe or unexpected symptoms occur, contact a qualified medical professional. PEPTIDES·INDEX does not provide medical advice.
- No human contraindications can be defined — SLU-PP-332 has never been given to humans and has no clinical safety, pharmacokinetic or toxicology data.
- No chronic-toxicity, cardiovascular-safety, reproductive or carcinogenicity studies exist even in animals; sustained pan-ERR activation is a theoretical cardiac/off-target concern because ERRs are highly expressed in the heart.
- Pregnancy, breastfeeding and any use in humans are unsupported by data.
- No documented human drug interactionsInteraction profile uncharacterized in humans (research use only).
Compare
- vs 5-Amino-1MQ
Other small-molecule metabolic research compound (NNMT inhibitor)
- vs MOTS-c
Mitochondrial-derived peptide studied for exercise/metabolic effects
FAQ
Has SLU-PP-332 been tested in humans?
No. It has never entered human trials. Every finding is preclinical (mouse and in-vitro), so none of the endurance or weight-loss results can be extrapolated to people. It is research-use-only and not FDA-evaluated.
What is an exercise mimetic?
It is a compound that reproduces some molecular and physiological effects of aerobic exercise without the organism exercising more. In mice, SLU-PP-332 increased oxidative muscle fibers, fat oxidation and endurance via ERRalpha signaling — but only in animals.
Is it a peptide, and can you take it as a tablet?
It is a small molecule, not a peptide, despite being sold as tablets. It is also poorly orally bioavailable in animals, which led the same lab to develop a successor (SLU-PP-915). The tablet framing does not reflect any validated human formulation.
How does SLU-PP-332 work?
It is a pan-agonist of the estrogen-related receptors ERRalpha/beta/gamma — orphan nuclear receptors that regulate cellular energy metabolism, including mitochondrial biogenesis, oxidative phosphorylation and fatty-acid oxidation. It is most potent at ERRalpha, and in mice it triggers an ERRalpha-dependent transcriptional program resembling acute aerobic exercise.
What did the animal studies actually show?
In mice, it produced ERRalpha-dependent endurance gains, and in obese mice it was reported to drive roughly 12% weight loss with improved glucose tolerance and reduced liver fat, without suppressing appetite. These are rodent and in-vitro results only and do not establish any human effect.
Is SLU-PP-332 safe to take?
Its human safety is entirely unknown — no clinical adverse-event, pharmacokinetic or toxicology data exist, and even animal data are limited to short-term dosing with no chronic-toxicity, cardiovascular, reproductive or carcinogenicity studies. Because ERRs are highly expressed in the heart, sustained pan-ERR activation is a specific, uncharacterized theoretical concern. It is strictly research-use-only.
Similar compounds
Starting references for the library summary. These are not dosing instructions or medical advice.
For research-use educational context only. Not medical advice and not a recommendation to use any compound. Consult a qualified healthcare professional before any health decision.